Optical Blood Pressure Monitoring Via Mobile Application, 3 Arms Swiss Clinical Study
Launched by BIOSPECTAL · Mar 13, 2019
Trial Information
Current as of April 29, 2025
Unknown status
Keywords
ClinConnect Summary
The purpose of the study is to compare the blood pressure values measured by a mobile application used with a smartphone and the values measured by reference equipments, which are the arterial line and the ausculatory sphygmomanometer .
In the arm 1 of the study, patients scheduled for general anesthesia at the Centre Hospitalier Universitaire Vaudois (CHUV) and at the Hôpitaux Universitaire de Genève (HUG) will be recruited and their pressure will be measured with both mesurement methods. General anesthesia is known to generate significant variations in blood pressure at the time of induc...
Gender
ALL
Eligibility criteria
- Arm 1, Inclusion Criteria:
- • Informed Consent as documented by signature
- • Men or women older than 18 years old
- • Good understanding of written and oral speaking used at the centre where the study will be carried out
- • American Society of Anesthesiology clinical classification Risk (ASA) Class 1-3
- • Scheduled for a general anesthesia
- • Necessitating an arterial catheters for the anesthesia and surgery.
- Arm 1, Exclusion Criteria:
- • Patients that cannot sign informed consent
- • Patients in emergency situation, are not legally competent, cannot understand the situation
- • ASA Risk class 4
- • Dyshythmia like bigeminy, trigeminy, isolated Ventricular Premature Beats (VPB), atrial fibrillation
- • Lesion or deficiency on hand, preventing index obstruction of smartphone's camera
- • Known contact dermatitis to nickel/chromium
- Arm 2, Inclusion Criteria:
- • Informed Consent as documented by signature
- • Men or women older than 18 years old
- • Good understanding of written and oral speaking used at the centre where the study will be carried out
- Arm 2,Exclusion Criteria:
- • Patients that cannot sign informed consent
- • Patients in emergency situation, are not legally competent, cannot understand the situation
- • Known or suspected non-compliance (e.g. drug or alcohol abuse, language problems, psychological disorders, dementia)
- • Known pregnancy
- • Systolic blood pressure difference between two arms \>15mmHg or, diastolic blood pressure difference between two arms \>10mmHg
- • Unstable cardiac condition (myocardial infarction \< 1 week, pulmonary embolism, ventricular arrhythmia, decompensated heart failure)
- • Dysrhythmia like bigeminy, trigeminy, isolated Ventricular Premature Beats (VPB), atrial fibrillation
- • Lesion or deficiency on hand, preventing index obstruction of smartphone's camera
- • Known contact dermatitis to nickel/chromium.
- Arm 3, Inclusion Criteria:
- • Informed Consent as documented by signature
- • Pregnant women older than 18 years old
- • Good understanding of written and oral speaking used at the centre where the study will be carried out
- • Scheduled for a prepartum anesthesia consultation at the hospital maternity unit
- Arm 3,Exclusion Criteria:
- • Patients that cannot sign informed consent
- • Patients in emergency situation, are not legally competent, cannot understand the situation
- • Known or suspected non-compliance (e.g. drug or alcohol abuse, language problems, psychological disorders, dementia)
- • Systolic blood pressure difference between two arms \>15mmHg or, diastolic blood pressure difference between two arms \>10mmHg
- • Unstable cardiac condition (myocardial infarction \< 1 week, pulmonary embolism, ventricular arrhythmia, decompensated heart failure)
- • Dysrhythmia like bigeminy, trigeminy, isolated Ventricular Premature Beats (VPB), atrial fibrillation
- • Lesion or deficiency on hand, preventing index obstruction of smartphone's camera
- • Known contact dermatitis to nickel/chromium.
About Biospectal
Biospectal is an innovative healthcare technology company dedicated to transforming cardiovascular health through advanced optical sensing solutions. By leveraging cutting-edge algorithms and non-invasive measurement techniques, Biospectal aims to deliver accurate and real-time blood pressure monitoring and health insights directly from smartphones. Their commitment to enhancing patient care and empowering individuals with accessible health data positions them at the forefront of digital health advancements. Through rigorous clinical trials, Biospectal seeks to validate the efficacy of its solutions, ensuring they meet the highest standards of safety and reliability for patients and healthcare providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, Vaud, Switzerland
Genève, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials